Cytomegalovirus reactivates in significant proportion of COVID-19 patients
30.6% of ICU patients experienced CMV reactivation.
Related Articles
Latest Conference
Contagion® is a fully integrated news resource for practitioners and specialists to assist with the identification, diagnosis, treatment, and prevention of infectious diseases.
What to know about the COVID variant that may cause ‘razor blade’ sore throats
The COVID-19 variant that may be driving a recent rise in cases in some parts of the world has earned a new nickname: “razor blade…
The world’s only twice-a-year shot to prevent HIV could stop transmission — if people can get it
WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect…
Meet the Anti-Vax ACIP First Round Draft Picks of 2025!
It’s MAHA fantasy season, so let’s take a look at this year’s rookie class. Which preventable disease will start killing children first?
Vaccine RCT spreadsheet aims to show the data, dispel myths about vaccines
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 Since late April, an infectious diseases specialist at Stanford University and his colleagues have been volunteering their time on a…
Reinforcing Support for Adolescent Girls and Young Women as PEPFAR Priorities Evolve | CSIS
Amid the dismantling and re-structuring of U.S. foreign assistance, policymakers can apply lessons from a decade of DREAMS programming to avert a resurgent HIV epidemic…
Clinical Evaluation of MAP-1 Antimicrobial Coating on Patient Privacy Curtains: Insights from a Randomized Trial in a Hong Kong Hospital
Microorganisms, including multidrug-resistant organisms (MDROs), can persist on hospital surfaces, posing significant health risks. Patient privacy curtains (PPCs) are particularly vulnerable due to their porous…
2025 Research-for-Cure Academy
The academy awards fellowships to up to 15 applicants to participate in a series of interactive workshops
HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval
A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One looming question: Will it be affordable…
